Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBITDA Margin: 2016-2025

Historic EBITDA Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to 0.92%.

  • Akebia Therapeutics' EBITDA Margin rose 5446.00% to 0.92% in Q3 2025 from the same period last year, while for Sep 2025 it was -7.07%, marking a year-over-year decrease of 31900.00%. This contributed to the annual value of -43.33% for FY2024, which is 47592.00% up from last year.
  • Per Akebia Therapeutics' latest filing, its EBITDA Margin stood at 0.92% for Q3 2025, which was up 132.41% from 0.40% recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' EBITDA Margin registered a high of 23.30% during Q2 2022, and its lowest value of -156.94% during Q2 2021.
  • Moreover, its 3-year median value for EBITDA Margin was -19.82% (2023), whereas its average is -26.12%.
  • Within the past 5 years, the most significant YoY rise in Akebia Therapeutics' EBITDA Margin was 27,750bps (2021), while the steepest drop was 6,438bps (2021).
  • Quarterly analysis of 5 years shows Akebia Therapeutics' EBITDA Margin stood at -121.13% in 2021, then soared by 11,024bps to -10.88% in 2022, then spiked by 1,041bps to -0.48% in 2023, then plummeted by 4,857bps to -49.04% in 2024, then skyrocketed by 5,446bps to 0.92% in 2025.
  • Its EBITDA Margin stands at 0.92% for Q3 2025, versus 0.40% for Q2 2025 and 10.66% for Q1 2025.